Anxiety, Depression, Menopausal Depression, Menopause, Primary Ovarian Insufficiency (Poi)
Conditions
Keywords
Menopause, Primary Ovarian Insufficiency (Poi), Anxiety, depression
Brief summary
Menopause is defined as the permanent cessation of menstrual cycles due to ovarian follicle depletion, typically occurring after age 50, and is associated with decreased estrogen levels. Primary ovarian insufficiency (POI) involves early ovarian dysfunction before age 40, with infertility as a key concern. Both menopause and POI may contribute to psychological symptoms, including anxiety and depression, influenced by sociodemographic and health factors. While literature reports anxiety in middle-aged women, data on its association with menopausal timing are limited. This study aims to compare women with POI and those undergoing natural menopause after age 40, assessing the relationship between age at menopause, anxiety, and depression, as well as the impact of fertility expectations on psychological well-being in POI patients.
Interventions
OTHERBeck Anxıety Inventory (BAI)
Beck Anxıety Inventory (BAI) Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.
OTHERState-Trait Anxiety Scale (STAI) 1-2
State-Trait Anxiety Scale (STAI) 1-2 Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.
Sponsors
Ankara City Hospital Bilkent
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
24 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy women over 24 years of age who visited our hospital for routine outpatient check-ups, had been diagnosed with menopause, and had no history of psychiatric disorders before menopause.
Exclusion criteria
* Cardiovascular diseases including hypertension * Type 1 or type 2 diabetes mellitus * Morbid obesity * Primary adrenal insufficiency * Uterine fibroids * Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease * Hepatic dysfunctions * Renal insufficiency * Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9 * Neurologic diseases * Psychiatric disorders * Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever * History of any malignancy * History of exposure to chemotherapeutic agents or radiotherapy * Individuals with a history of chronic or regular medication use that could cause anxiety or depression symptoms * Individuals with a personal history of psychiatric disorders * Individuals with a history of depression in the past 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Beck Anxıety Inventory (BAI), Anxiety level | Baseline (single assessment at enrollment during routine clinic visit). | Anxiety severity measured by the Beck Anxiety Inventory (BAI) during routine clinic visit. |
| State-Trait Anxiety Scale (STAI) 1-2, Anxiety level | Baseline (single assessment at enrollment during routine clinic visit). | Anxiety severity measured by the State-Trait Anxiety Inventory (STAI) forms 1 and 2 during routine clinic visit. |
Countries
Turkey (Türkiye)
Outcome results
None listed